ResearcherIRCCS Ospedale San RaffaeleNo recent work listed
Daniela Liberati
Matched on OpenAlex author ID A5108637390. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper
Papers 8
- Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. Co-author DOI 10.1007/s00592-019-01335-4↗
- Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with c… Co-author DOI 10.1016/j.pan.2018.09.006↗
- Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Co-author DOI 10.1093/carcin/bgy094↗
- No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Co-author DOI 10.3233/cbm-181218↗
- A preoperative score to predict early death after pancreatic cancer resection. Co-author DOI 10.1016/j.dld.2017.06.012↗
- Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Co-author DOI 10.1016/j.pan.2016.08.005↗
- (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Co-author DOI 10.1158/1078-0432.ccr-15-1722↗
- Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. Co-author DOI 10.1371/journal.pone.0166008↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Valentina Pasquale · 8 shared papers, 2016–2019 · strength 0.52
- Paper Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. DOI 10.1007/s00592-019-01335-4↗
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Erica Dugnani · 8 shared papers, 2016–2019 · strength 0.52
- Paper Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. DOI 10.1007/s00592-019-01335-4↗
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Lorenzo Piemonti · 8 shared papers, 2016–2019 · strength 0.52
- Paper Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. DOI 10.1007/s00592-019-01335-4↗
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Gianpaolo Balzano · 6 shared papers, 2016–2018 · strength 0.35
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper A preoperative score to predict early death after pancreatic cancer resection. DOI 10.1016/j.dld.2017.06.012↗
- Massimo Falconi · 6 shared papers, 2016–2018 · strength 0.35
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper A preoperative score to predict early death after pancreatic cancer resection. DOI 10.1016/j.dld.2017.06.012↗
- Michele Reni · 6 shared papers, 2016–2018 · strength 0.35
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper A preoperative score to predict early death after pancreatic cancer resection. DOI 10.1016/j.dld.2017.06.012↗
- Claudio Doglioni · 6 shared papers, 2016–2018 · strength 0.35
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ul… DOI 10.1093/carcin/bgy094↗
- Paper A preoperative score to predict early death after pancreatic cancer resection. DOI 10.1016/j.dld.2017.06.012↗
- Vito Lampasona · 3 shared papers, 2016–2018 · strength 0.20
- Paper No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. DOI 10.3233/cbm-181218↗
- Paper Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected… DOI 10.1016/j.pan.2018.09.006↗
- Paper (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II … DOI 10.1158/1078-0432.ccr-15-1722↗
- Francesco De Sanctis · 1 shared paper, 2018 · strength 0.07
- Massimo Venturini · 1 shared paper, 2018 · strength 0.07
- Giulio Belfiori · 1 shared paper, 2017 · strength 0.06
- Stefano Crippa · 1 shared paper, 2017 · strength 0.06
- Stefano Cereda · 1 shared paper, 2016 · strength 0.05
- Carmen Belli · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.